Samuel Engel discusses Merck's VERTIS clinical trial program and recent ertugliflozin research including the VERTIS SITA study and the VERTIS MET study,

In this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the results of studies related to ertugliflozin.

In part 1 of this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the results of the new SGLT-2, ertugliflozin.

In part 2 of this Exclusive Interview, Dr. Samuel Engel explains the effects of ertugliflozin on typical biometrics in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.

In part 3 of this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the cardiovascular study portion of the ertugliflozin trial.

In part 4 of this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about looking at the impact of DPP-4s on hypoglycemia.

In part 5, the conclusion of this Exclusive Interview, Dr. Osama Hamdy talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the coming ease of managing diabetes consistently no matter which country a person with diabetes lives in or visits.

In this Exclusive Interview, Dr. Osama Hamdy talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the importance of understanding and working with various cultural traditions in order to effectively manage diabetes anywhere in the world.

Joel Goldsmith is the Senior Director of Digital Platforms at Abbott Diabetes Care, which is focused on designing, developing, and commercializing software-based products and services that drive trial and sustained utilization of ADC's sensor-based glucose monitoring solutions. He and his team created the FreeStyle Libre system, which comprises a tiny glucose sensor (0.2 inches in length, about the thickness of a hair) inserted through the skin and connected to a small, water resistant, plastic patch on the skin’s surface.

In this Exclusive Interview, Joel Goldsmith talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the new Freestyle Lite and Freestyle Pro CGM systems, their benefit to patients as well as clinicians, and the response thus far.